The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

Kay, Stanley R.; Fiszbein, Abraham; Opler, Lewis A.

doi:10.1093/schbul/13.2.261

Cited by 18,173 publications

(11,545 citation statements)

References 46 publications

Supporting

Mentioning

11,209

Contrasting

Unclassified

242

Order By: Relevance

“…Assessment of the patient’s clinical state was performed using the Positive and Negative Syndrome Scale (PANSS) [37,38], which includes 30 items, scored on a seven-point severity scale, that provide an overall score for positive symptoms (seven items) and negative symptoms (seven items), and a general measure of psychopathology (16 items) [14]. The questionnaire is interviewer-administered, requiring a 30–40 minute semi-formal psychiatric interview [38].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Healthcare resource use in schizophrenia, EuroSC findings

Millier

Horváth

Kóczián

et al. 2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

Background: It is unclear if the burden associated with schizophrenia is affected by the type and severity of patient’s symptoms. Objective: This study aims to quantify healthcare resource use associated with different profiles of schizophrenia symptoms. Study design: Post-hoc analysis of data from a naturalistic follow-up study. Setting: Secondary psychiatric services in France, Germany and the UK. Patients: EuroSC cohort:, representative sample of 1,208 schizophrenia patients Main outcome measure: We classified patients into eight health states, according to the Lenert classification (HS1–HS8), and estimated 6-month healthcare resource use (outpatient and day clinic visits, and hospitalisations) across the health states. Results: Approximately half of the patients were classed as having mild symptoms (HS1), with around 20% experiencing moderate, predominantly negative symptoms (HS2). The remaining health states were represented by <10% of patients each. Very few patients experienced extremely severe symptoms (HS8). No health state was associated with excess utilisation across all resource types. In terms of outpatient visits, patients were estimated to see a psychiatrist most often (3.01–4.15 visits over 6 months). Hospital admission was needed in 11%(HS1) – 35%(HS8) of patients and inpatient stays were generally prolonged for all health states (39–57 days). The average number of inpatient days was highest for patients in HS8 (18.17 days), followed by patients with severe negative symptoms (HS4; 13.37 days). In other health states characterised by severe symptoms (HS5–HS7), the average number of inpatient days was approximately half of those seen for HS4 (6.09–7.66). Conclusion: While none of the symptom profiles was associated with excess resource usage, hospitalization days were highest for HS with severe, predominantly negative or extremely severe symptoms. Patients with predominantly negative, moderate or severe symptoms appeared to have a high number of psychologist visits – an interesting finding that may reflect a specific therapeutic approach to the treatment of these patients.

show abstract

Section: Methodsmentioning

confidence: 99%

“…The questionnaire is interviewer-administered, requiring a 30–40 minute semi-formal psychiatric interview [38]. Responses are based on patient experiences over a pre-specified period preceding the interview, usually 1 week [38]. …”

Section: Methodsmentioning

confidence: 99%

Healthcare resource use in schizophrenia, EuroSC findings

Millier

Horváth

Kóczián

et al. 2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

show abstract

“…This analysis involved multiple statistical tests, including repeated measures analysis, to assess whether patients with greater symptomatology at baseline were more likely to show change with treatment 13. The analysis of this population considered Marder factors and included an assessment of dose (≤20 mg, ≥50 mg) using a repeated measures analysis of covariance and a Tukey post hoc analysis.…”

Section: Methodsmentioning

confidence: 99%

Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia

Cantillon¹,

Ings²,

Bhat³

2018

Clinical Translational Sci

View full text Add to dashboard Cite

RP5063 is a multimodal dopamine (D)‐serotonin (5‐HT) stabilizer with a high affinity for D2/3/4 and 5‐HT1A/2A/2B/7 receptors and moderate affinity for the serotonin transporter. Single‐dose (10 and 15 mg fasting, 15 mg fed) safety in healthy volunteers and multiple‐dose (10, 20, 50, and 100 mg fed, 10 days) safety and pharmacodynamics in patients with stable schizophrenia were defined in two phase I studies. In the single‐dose study, 32 treatment‐emergent adverse events (TEAEs) were observed. Orthostatic hypotension (n = 6), nausea (n = 5), and dizziness (n = 4) were the most common. One serious adverse event (SAE), seen in a patient who should not have been in the study due to a history of seizures, involved brief seizure‐like symptoms. In the multiple‐dose study, 75 TEAEs were reported. Akathisia (n = 20) and somnolence (n = 14) were the most frequent. No clinically significant changes were seen in glucose or prolactin levels, lipid profiles, weight, or electrocardiographic recordings. In both studies, all TEAEs resolved and none led to withdrawal from the study or death. A pharmacodynamic evaluation reflected significant improvements with RP5063 (P < 0.05) over placebo in an analysis of patients with a baseline Positive and Negative Syndrome Scale (PANSS) score ≥50 for positive subscale scores. Improvements of the Trail Making A and Trail Making B test results were observed for patients treated in the 50 mg dose group for days 5, 10, and 16. These findings indicate that RP5063 is well‐tolerated up to 100 mg and displays promising preliminary clinical behavioral and cognition activity signals in patients with stable disease over a 10‐day period.

show abstract

“…The short form of the Korean‐Wechsler Adult Intelligence Scale was used to evaluate IQ (Yeom, Park, Oh, & Lee, 1992). The patients' symptom severities were assessed with the Positive and Negative Syndrome Scale (Kay, Flszbein, & Opfer, 1987). All of the patients were taking at least one antipsychotic medication, and their symptoms and medication doses were stable at the time of the study.…”

Section: Methodsmentioning

confidence: 99%

Aberrant neural networks for the recognition memory of socially relevant information in patients with schizophrenia

Chun

Kim

et al. 2016

Brain and Behavior

View full text Add to dashboard Cite

IntroductionPatients with schizophrenia exhibit several cognitive deficits, including memory impairment. Problems with recognition memory can hinder socially adaptive behavior. Previous investigations have suggested that altered activation of the frontotemporal area plays an important role in recognition memory impairment. However, the cerebral networks related to these deficits are not known. The aim of this study was to elucidate the brain networks required for recognizing socially relevant information in patients with schizophrenia performing an old–new recognition task.MethodsSixteen patients with schizophrenia and 16 controls participated in this study. First, the subjects performed the theme‐identification task during functional magnetic resonance imaging. In this task, pictures depicting social situations were presented with three words, and the subjects were asked to select the best theme word for each picture. The subjects then performed an old–new recognition task in which they were asked to discriminate whether the presented words were old or new. Task performance and neural responses in the old–new recognition task were compared between the subject groups. An independent component analysis of the functional connectivity was performed.ResultsThe patients with schizophrenia exhibited decreased discriminability and increased activation of the right superior temporal gyrus compared with the controls during correct responses. Furthermore, aberrant network activities were found in the frontopolar and language comprehension networks in the patients.ConclusionsThe functional connectivity analysis showed aberrant connectivity in the frontopolar and language comprehension networks in the patients with schizophrenia, and these aberrations possibly contribute to their low recognition performance and social dysfunction. These results suggest that the frontopolar and language comprehension networks are potential therapeutic targets in patients with schizophrenia.

show abstract

The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia

Cited by 18,173 publications

References 46 publications

Healthcare resource use in schizophrenia, EuroSC findings

Healthcare resource use in schizophrenia, EuroSC findings

Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia

Aberrant neural networks for the recognition memory of socially relevant information in patients with schizophrenia

Contact Info

Product

Resources

About